10q10k10q10k.net
Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.CRNXEarnings & Financial Report

Nasdaq

Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.

NextMar 30, 2026

CRNX Q3 2025 Key Financial Metrics

Revenue

$143.0K

Gross Profit

N/A

Operating Profit

$-142.6M

Net Profit

$-130.1M

Gross Margin

N/A

Operating Margin

-99710.5%

Net Margin

-90972.7%

YoY Growth

N/A

EPS

$-1.38

Financial Flow

Crinetics Pharmaceuticals, Inc. Q3 2025 Financial Summary

Crinetics Pharmaceuticals, Inc. reported revenue of $143.0K for Q3 2025, with a net profit of $-130.1M (-90972.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$143.0K
Net Profit$-130.1M
Gross MarginN/A
Operating Margin-99710.5%
Report PeriodQ3 2025

Crinetics Pharmaceuticals, Inc. Annual Revenue by Year

Crinetics Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $0).

YearAnnual Revenue
2022$0

Income Statement

Q2 2023Q3 2023Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Revenue$988000$346000$640000$399000$0$361000$1.0M$143000
YoY Growth125.1%-24.5%-76.1%-59.6%N/A-43.6%158.4%N/A

Balance Sheet

Q2 2023Q3 2023Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Assets$293.3M$641.5M$978.2M$935.5M$937.4M$1.36B$1.29B$1.20B
Liabilities$39.1M$93.8M$103.2M$104.8M$104.4M$107.3M$118.0M$123.9M
Equity$254.1M$547.7M$874.9M$830.8M$833.0M$1.25B$1.17B$1.07B

Cash Flow

Q2 2023Q3 2023Q1 2024Q2 2024Q3 2024Q1 2025Q2 2025Q3 2025
Operating CF$-45.7M$-41.3M$-52.9M$-45.6M$-62.8M$-88.5M$-85.9M$-110.7M